NALIRIFOX Worth Consideration in Pancreatic Ductal Adenocarcinoma, Says Expert

Video

An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.

First-line liposomal irinotecan (Onivyde) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX), if approved by the FDA, should considered as a treatment option for average patients with metastatic pancreatic ductal adenocarcinoma, according to Zev. A. Wainberg, MD.

CancerNetwork® spoke with lead author, Wainberg, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the UCLA Gastrointestinal Oncology Program, about his takeaways from the phase 3 NAPOLI-3 study (NCT04083235), the data from which he presented at the 2023 Gastrointestinal Cancers Symposium.

In particular, he noted that meeting end points in pancreatic cancer trials has been a historical challenge, and that the positive findings from the NAPOLI-3 trial should be considered despite not being as impressive as originally hoped. Additionally, the trial answered an important question regarding the NALIRIFOX’s superiority.

Transcript:

We answered a question for the community, and it’s important to do that; it’s important to answer questions as to what the optimal regimen in a disease like metastatic pancreatic cancer. In this trial, we certainly did answer this question conclusively: NALIRIFOX is superior to gemcitabine and nab-paclitaxel for overall survival and with a different trade-off in toxicity.

For an average patient with an ECOG performance status of 0 [or] 1, this regimen, if approved, should be considered. It’s very hard to prove your end point of overall survival in pancreatic cancer studies; it has been done rarely throughout the history of this disease. When it does happen, even if the results were not as, in some ways, exciting as many of us would have hoped, we need to take those results in mind.

Reference

Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2023;41(suppl 4):LBA661. doi:10.1200/JCO.2023.41.3_suppl.LBA661

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.